IMPEDIMED LIMITED — Capital/Financing Update 2011

Oct 19, 2011

==> picture [110 x 104] intentionally omitted <==

----- Start of picture text ----- ASX: IPD----- End of picture text -----

Thursday 20 October 2011

Australian Securities Exchange Announcement

ADDITIONAL COVERED LIVES

ImpediMed announces additional covered lives from a third-party administrator (TPA) offering coverage for L-DEX® testing.

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (ImpediMed or the Company) reports today additional coverage for bioimpedance spectroscopy. Group & Pension Administrators, Inc., (GPA) is one of the largest independently owned third-party benefit administrators or TPA’s in the Southwestern United States and is an active promoter of women's health. GPA covers 175,000+ lives through the selfinsured companies it provides services. In a press release issued today in the US, GPA stated that it strongly endorses the pre-emptive model of care for lymphedema in breast cancer patients.

"As a wellness and prevention champion, GPA strongly promotes health plan coverage for oncologists to clinically assess the early stages of Lymphedema because it is the right thing to do for the patient and plan," said Kathy Enochs, COO for GPA.

Greg Brown, ImpediMed’s CEO stated, “In today’s US healthcare environment, growing numbers of companies see becoming self-insured as a means of controlling cost while improving quality of care for employees. We are excited by the announcement which demonstrates GPA’s focus on women’s health issues and because of their prominence in the Southwest. They recognized the value of the pre-emptive model of care, and the use of L-Dex as an aid in the clinical assessment of unilateral lymphoedema of the arm in women.”

The electronically published GPA announcement can be found at the following link:

http://www.gpatpa.com/10_18_11_gpa_promotes_early_detection.htm

This announcement is important to the Company as it demonstrates acceptance by a segment of the US healthcare market responsible for paying medical claims filed by physicians treating the employees of self-insured companies. ImpediMed’s U400 L-Dex device, used by a medical provider, can aid in the clinical assessment of unilateral lymphoedema of the arm in women, by measuring extracellular fluid differences of the limbs.

Greg Brown CEO

ENDS

Page 1 of 2

For further information contact:

Greg Brown ImpediMed CEO T: 61-7-3860-3700 Mobile/Cell: +61408281127

L-Dex[®] is a trademark of ImpediMed Limited.

The L-Dex scale is a tool to aid in the clinical assessment of unilateral lymphoedema of the arm in women by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.

For more information, visit: www.impedimed.com.

Page 2 of 2